

R Rissmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5204332/publications.pdf>

Version: 2024-02-01

65
papers

1,386
citations

448610

19
h-index

406436

35
g-index

65
all docs

65
docs citations

65
times ranked

2441
citing authors

#	ARTICLE	IF	CITATIONS
1	Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 854-862.	0.6	17
2	Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 680-690.	1.1	8
3	Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 964-971.	2.3	3
4	OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof of Pharmacology for KY1005. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1121-1132.	2.3	18
5	Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. <i>Cancers</i> , 2022, 14, 1510.	1.7	1
6	A Systematic Review on Disease-Drug-Drug Interactions with immunomodulating drugs: A Critical Appraisal of Risk Assessment and Drug Labelling. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	3
7	Results of a randomized, placebo-controlled, first-in-human trial of topical CY002 in patients with cutaneous warts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	0
8	A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1953-1962.	1.1	9
9	Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3162-3176.	1.1	11
10	Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et al.. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2633-2634.	1.1	1
11	Integrin $\alpha 6$ as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions. <i>Cancers</i> , 2021, 13, 6006.	1.7	1
12	The Human Vulvar Microbiome: A Systematic Review. <i>Microorganisms</i> , 2021, 9, 2568.	1.6	8
13	Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 633-639.	1.3	16
14	No effect of topical digoxin and furosemide gel for patients with external anogenital warts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e45-e46.	1.3	2
15	Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2133-2143.	1.1	9
16	Blueprint for mechanistic, data-rich early phase clinical pharmacology studies in dermatology. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1011-1014.	1.1	7
17	Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers. <i>Clinical and Translational Science</i> , 2020, 13, 573-579.	1.5	15
18	Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: A systematic review of candidate biomarkers. <i>Gynecologic Oncology</i> , 2020, 156, 734-743.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll-Like Receptor Ligands in Human Peripheral Blood Mononuclear Cells. <i>Clinical and Translational Science</i> , 2020, 13, 891-895.	1.5	5
20	Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial. <i>Clinical and Translational Science</i> , 2020, 13, 994-1003.	1.5	24
21	Inter- and Intra-patient Variability Over Time of Lesional Skin Microbiota in Adult Patients with Atopic Dermatitis. <i>Acta Dermato-Venereologica</i> , 2020, 100, 1-2.	0.6	3
22	Underrepresentation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 838-844.	1.1	55
23	Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1389-1390.	1.1	3
24	Stereophotogrammetric three-dimensional photography is an accurate and precise planimetric method for the clinical visualization and quantification of human papilloma virus-induced skin lesions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1506-1512.	1.3	7
25	A randomized controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts. <i>British Journal of Dermatology</i> , 2019, 180, 1058-1068.	1.4	19
26	The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects. <i>European Journal of Pain</i> , 2019, 23, 874-883.	1.4	9
27	The effect of repeated methotrexate injections on the quality of life of children with rheumatic diseases. <i>European Journal of Pediatrics</i> , 2019, 178, 17-20.	1.3	17
28	Gender differences in clinical registration trials: is there a real problem?. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 700-707.	1.1	62
29	Morphological characteristics and human papillomavirus genotype predict the treatment response in cutaneous warts. <i>British Journal of Dermatology</i> , 2018, 178, 253-260.	1.4	28
30	Reply to correspondence "Topical ionic antiviral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts". <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e156.	1.3	0
31	Developing and validating the Cutaneous WARTS (CWARTS) diagnostic tool: a novel clinical assessment and classification system for cutaneous warts. <i>British Journal of Dermatology</i> , 2018, 178, 527-534.	1.4	12
32	Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development. <i>Clinical and Translational Science</i> , 2018, 11, 607-615.	1.5	12
33	Essential diseases in prescribing: A national Delphi study towards a core curriculum in pharmacotherapy education. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2645-2650.	1.1	10
34	Complement Activation in Inflammatory Skin Diseases. <i>Frontiers in Immunology</i> , 2018, 9, 639.	2.2	76
35	A systematic literature review of the human skin microbiome as biomarker for dermatological drug development. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2178-2193.	1.1	26
36	Clinical Pharmacology Research Internships at the Interface between Academia and Industry: Students' Perceptions and Scientific Output. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 22-28.	1.2	0

#	ARTICLE	IF	CITATIONS
37	An anti- ϵ -nicotinic cognitive challenge model using mecamylamine in comparison with the anti- μ -muscarinic cognitive challenge using scopolamine. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1676-1687.	1.1	13
38	Pharmacokinetics and pharmacodynamics of oral mecamylamine – development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. <i>Journal of Psychopharmacology</i> , 2017, 31, 192-203.	2.0	5
39	Pharmacovigilance Skills, Knowledge and Attitudes in our Future Doctors – A Nationwide Study in the Netherlands. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 475-481.	1.2	19
40	Topical ionic contra-viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2088-2090.	1.3	14
41	IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. <i>Clinical Immunology</i> , 2017, 174, 63-72.	1.4	74
42	European drug market entries 2015 with new mechanisms of action. <i>Clinical Medicine</i> , 2016, 16, 475-480.	0.8	2
43	Olaparib. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 171-173.	1.1	15
44	Sofosbuvir and daclatasvir. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 878-879.	1.1	4
45	Injection site reactions after subcutaneous oligonucleotide therapy. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 340-351.	1.1	33
46	Vemurafenib/dabrafenib and trametinib. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 765-767.	1.1	18
47	Bedaquiline. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 182-184.	1.1	8
48	Lomitapide. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 179-181.	1.1	23
49	Mirabegron. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 762-764.	1.1	3
50	Combined LC/MS-platform for analysis of all major stratum corneum lipids, and the profiling of skin substitutes. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 70-79.	1.2	94
51	Concept-based learning of personalized prescribing. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 589-596.	1.1	12
52	Tolvaptan. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 9-11.	1.1	1
53	Riloncept and canakinumab. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 639-641.	1.1	55
54	Denosumab. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 804-806.	1.1	14

#	ARTICLE	IF	CITATIONS
55	Skin barrier disruption by acetone: observations in a hairless mouse skin model. Archives of Dermatological Research, 2009, 301, 609-613.	1.1	37
56	Development of a murine model to evaluate the effect of vernix caseosa on skin barrier recovery. Experimental Dermatology, 2009, 18, 178-184.	1.4	34
57	Mimicking vernix caseosaâ€”Preparation and characterization of synthetic biofilms. International Journal of Pharmaceutics, 2009, 372, 59-65.	2.6	14
58	Long periodicity phase in extracted lipids of vernix caseosa obtained with equilibration at physiological temperature. Chemistry and Physics of Lipids, 2009, 158, 32-38.	1.5	4
59	Effect of synthetic vernix biofilms on barrier recovery of damaged mouse skin. Experimental Dermatology, 2009, 18, 695-703.	1.4	16
60	Temperature-Induced Changes in Structural and Physicochemical Properties of Vernix Caseosa. Journal of Investigative Dermatology, 2008, 128, 292-299.	0.3	16
61	Lanolin-derived lipid mixtures mimic closely the lipid composition and organization of vernix caseosa lipids. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 2350-2360.	1.4	34
62	Preparation and Characterization of Structured Hydrogel Microparticles Based on Cross-Linked Hyperbranched Polyglycerol. Langmuir, 2007, 23, 11819-11825.	1.6	50
63	Synthesis of methacrylated hyaluronic acid with tailored degree of substitution. Polymer, 2007, 48, 1915-1920.	1.8	91
64	New Insights into Ultrastructure, Lipid Composition and Organization of Vernix Caseosa. Journal of Investigative Dermatology, 2006, 126, 1823-1833.	0.3	81
65	Synthesis and characterization of hyperbranched polyglycerol hydrogels. Biomaterials, 2006, 27, 5471-5479.	5.7	99